J&J positions its PARP combo Akeega in new prostate cancer subset with 2nd FDA nod

Akeega, a dual-action tablet made up of J&J's Zytiga and GSK's PARP inhibitor Zejula, is the first precision medicine combo approved to treat patients with BRCA2-mutated metastatic castration-sensitive prostate cancer.